Oil Prices Surge as U.S.-Iran Diplomacy Hopes Fade 
Mercedes-Benz Eyes €800 Million Labor Cost Cuts in Germany 
SoftBank Raises $11.1 Billion in Bond Sale to Fund OpenAI Investment 
Soybean Futures Slip as Traders Await Trump-Xi Trade Signals 
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
China’s ‘Lipstick King’ Says AI Won’t Replace Livestream Hosts 
BMW 2028 Margin Target Could Fall Below Consensus, UBS Says 
US, China Extend Trade Truce to Jan. 10 Ahead of Trump-Xi Summit 
Oil Prices Ease as Iran Tensions Clash With Diplomacy Hopes 
Tesla Semi Rollout Begins at Nevada Factory 
US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold 
Anthropic’s Claude Discovers CRISPR-Like Enzyme System 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
U.S. Dollar Hits Two-Month High as Oil, Treasury Yields Surge 
Microsoft Stock Upgraded as Stifel Sees Stronger Azure Growth 
Add as a preferred source on Google
SK Holdings revealed its acquisition of a French drug-maker called Yposkesi this week. The third-largest conglomerate in South Korea made the purchase in its bid to strengthen its competitive power in the global market’s biotech sector.
Moreover, SK has acquired French drug manufacturer Yposkesi to expand into the rapidly growing contract manufacturing organization (CMO) business, the newly renamed holding company of SK Group said Wednesday.
SK completed the acquisition
The Korea Times reported that SK acquired 70% percent shares, and this includes management rights in the French company. The acquisition came four months after the South Korean company said it is in talks to purchase Yposkesi.
The price of the deal was not mentioned in the reports, so there is no clear figure how much SK shelled out for the acquisition. The deal has been completed, and Yposkesi will now be operated by SK Pharmteco, a CMO subsidiary owned by SK Inc. based in Sacramento.
"We are glad to advance into the gene therapy CMO business by investing in Yposkesi which has great capability and potential," Jang Dong Kyun, SK’s chief executive officer, said. "We will spare no efforts to help Yposkesi grow fast in the global market."
About Yposkesi
Yposkesi, the French cell, and gene therapy company, is also one of the largest Contract Development & Manufacturing Organizations (CDMO) in Europe. With the purchase of this company, SK will now be able to supply innovative drugs around the world through creating a contract manufacturing organization (CMO) business system, as per Aju Business Daily.
Yposkesi was launched in 2016 by AFM-Téléthon and by the SPI fund managed by Bpifrance. It is the first French firm to develop and produce gene and cell therapy products. The company’s goal is to create the first treatments available to patients then sell them for a fair price.
Meanwhile, this is SK Holding’s third acquisition deal in the global CMO industry as it aims to be one of the best players in the biotechnology industry. Its purchase of pharma and biotech companies shows its determination to rise above in the market for this field.
"SK plans to complete the value chain of its synthetic and biopharmaceutical CMO business in the U.S., Europe and Asia by 2025," SK’s head in bio investment center, Lee Dong Hoon, said. "We will foster SK Pharmteco as a global leading CMO that can supply synthetic, gene and cell therapy drugs to the global pharmaceutical market."
